AL-001
/ Anlong Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 21, 2025
Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD
(clinicaltrials.gov)
- P2 | N=40 | Not yet recruiting | Sponsor: Beijing Anlong Biopharmaceutical Co., Ltd.
New P2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
December 05, 2024
Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
(clinicaltrials.gov)
- P=N/A | N=21 | Recruiting | Sponsor: Beijing Anlong Biopharmaceutical Co., Ltd.
New trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
November 27, 2024
Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD
(clinicaltrials.gov)
- P1/2 | N=21 | Active, not recruiting | Sponsor: Beijing Anlong Biopharmaceutical Co., Ltd.
New P1/2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
1 to 3
Of
3
Go to page
1